Document is current
Any future updates will be listed below
-
Authors
Yan, Wei
Guo, Ruiyun
Liu, Tong
Liu, Yukun
Ping, Rui
Liu, Boxin
He, Jingjing
Griffin, Matthew D.
Hynes, Seán O.
Shen, Sanbing
Liu, Yan
Ma, Jun https://orcid.org/0000-0003-2843-0769
O’Brien, Timothy https://orcid.org/0000-0001-9028-5481
- License Information
-
More Information
Article History
Received: 15 March 2025
Accepted: 16 December 2025
First Online: 27 December 2025
Declarations
:
: The experiments were conducted in accordance with the National Institutes of Health guidelines for the care of animals. The animal studies came from the project of "Effect and Mechanism of Mesenchymal Stem Cell in the Treatment of Diabetic Complications”and was approved by the Laboratory Animal Ethical and Welfare Committee of Hebei Medical University (Approval No. IACUCHebmu-2021035, Date: 8 December 2021). UC-MSC cells were obtained from Qilu Cell Therapy Technology (Shandong, China) and the company obtained the cells with ethical approval and patient consent(Approval No. CXSL2300854).
: Not applicable.
: TOB is global co-editor in chief of Stem Cell Research and Therapy. He will have no involvement in the peer review process or decisions on this article. He is also a Director and equity holder in Orbsen Therapeutics, a stem cell company. MD Griffin reports honoraria from the American Society of Nephrology; Théa Pharma Ltd., Ireland; and Novo Nordisk; research funding from Orbsen Therapeutics Ltd.; and advisory roles as an Editorial Board member for the journals Transplantation and Frontiers in Pharmacology and an Associate Editor for Mayo Clinic Proceedings. The other authors declare that they have no competing interests.
